Breast diseases

PubMed Free Full Text

Breast cancer treatment: endocrine therapy

Australia

• PLoS ONE
  • Women Commencing Anastrozole, Letrozole or Tamoxifen for Early Breast Cancer: The Impact of Comorbidity and Demographics on Initial Choice [2014]

Australia, New Zealand

• Royal Australian and New Zealand College of Obstetricians and Gynaecologists
  • Tamoxifen and the endometrium [2019]

Canada

• Cancers
  • Efficacy of Fulvestrant in Women with Hormone-Resistant Metastatic Breast Cancer (mBC): A Canadian Province Experience [2021]

• Current Oncology
  • An Overview of Long-Acting GnRH Agonists in Premenopausal Breast Cancer Patients: Survivorship Challenges and Management [2024]
  • Endocrine therapy for postmenopausal women with hormone receptor–positive her2–negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: a Canadian consensus statement [2013]

• Ontario Health
  • Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline [2015]
  • Tamoxifen
  • Letrozole
  • Fulvestrant
  • Exemestane
  • Anastrozole

China

• Clinical Breast Cancer
  • Cost-Effectiveness Analysis of Adjuvant Endocrine Therapy With Ovarian Suppression in Premenopausal Patients With Hormone Receptor-Positive Early Breast Cancer in China [2024]

• Frontiers in Oncology
  • Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China [2021]

• Journal of Cachexia, Sarcopenia and Muscle
  • Cost-Effectiveness of Fracture Prevention in Postmenopausal Women With Early Breast Cancer in China [2025]

• OncoTargets and Therapy
  • Clinical utility of letrozole in the treatment of breast cancer: a Chinese perspective [2016]

Europe

• Breast
  • Patient database analysis of fulvestrant 500 mg in the treatment of metastatic breast cancer: A European perspective [2017]

• Clinical Breast Cancer
  • A European, Observational Study of Endocrine Therapy Administration in Patients With an Initial Diagnosis of Hormone Receptor-Positive Advanced Breast Cancer [2017]

• European Medicines Agency
  • Faslodex

France

• BMC Medicine
  • Are breast cancer patients with suboptimal adherence to cardiovascular treatment more likely to discontinue adjuvant endocrine therapy? Competing risk survival analysis in a nationwide cohort of postmenopausal women [2023]

High-income countries

• Cancer Reports
  • Tamoxifen use and risk of endometrial cancer in breast cancer patients: A systematic review and dose-response meta-analysis [2023]

International

• Breast
  • The effects of adjuvant endocrine therapy on long-term outcomes from ductal carcinoma in situ: a systematic review and meta-analysis [2025]
  • The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: A quantitative systematic review [2022]
  • Factors influencing five-year adherence to adjuvant endocrine therapy in breast cancer patients: A systematic review [2022]

• Cancer Genomics & Proteomics
  • Pharmacogenetics of Toxicities Related to Endocrine Treatment in Breast Cancer: A Systematic Review and Meta-analysis [2024]

• Cancer Medicine
  • Fulvestrant in the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: A review [2019]

• Cancer Treatment Reviews
  • Revisiting ovarian function suppression with GnRH agonists for premenopausal women with breast cancer: Who should use and the impact on survival outcomes [2024]

• Clinical Pharmacology & Therapeutics
  • Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy [2018]

• Cochrane Database of Systematic Reviews
  • Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer [2022]
  • Fulvestrant for hormone-sensitive metastatic breast cancer [2017]

• Current Oncology
  • Risk of Cardiovascular Events and Lipid Profile Change in Patients with Breast Cancer Taking Aromatase Inhibitor: A Systematic Review and Meta-Analysis [2023]

• Frontiers in Oncology
  • Treatment of Breast Cancer With Gonadotropin-Releasing Hormone Analogs [2019]

• Journal of Cancer Survivorship
  • Strategies to self-manage side-effects of adjuvant endocrine therapy among breast cancer survivors: an umbrella review of empirical evidence and clinical guidelines [2022]

Italy

• BMC Cancer
  • An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project [2018]

Netherlands

• Breast
  • Less endocrine therapy in HR+/HER2- breast cancer: a nationwide trend despite unchanged guidelines [2026]

Republic of Korea

• Frontiers in Oncology
  • Effect of Tamoxifen on the Risk of Osteoporosis and Osteoporotic Fracture in Younger Breast Cancer Survivors: A Nationwide Study [2020]

• Journal of the American Heart Association
  • Effects of Endocrine Therapy on Cardiovascular Diseases and Type 2 Diabetes Among Breast Cancer Survivors: The National Health Insurance Service Database of Korea [2022]

South Africa

• Breast Cancer Research and Treatment
  • The impact of HIV on non-adherence for tamoxifen among women with breast cancer in South Africa [2023]

Sweden

• Acta Oncologica
  • Adherence to adjuvant endocrine therapy after breast cancer in Sweden - a nationwide cohort study in 1-, 3- and 5-year survivors with a focus on regional differences [2024]

• Breast
  • Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy [2023]

Taiwan

• Cancer Medicine
  • Gonadotropin-releasing hormone agonist treatment and ischemic heart disease among female patients with breast cancer: A cohort study [2023]

• PLoS ONE
  • Is tamoxifen good enough for the Asian population in ER+ HER2- post-menopausal women with early breast cancer? A nationwide population-based cohort study [2024]

United Kingdom

• Breast
  • Management and outcomes for older women with early breast cancer treated with primary endocrine therapy (PET) [2024]

• National Institute for Health and Care Excellence
  • Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment [2025]
  • Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer [2018]
  • Fulvestrant for the treatment of locally advanced or metastatic breast cancer [2011]

United States

• American College of Medical Genetics and Genomics
  • Laboratory testing of CYP2D6 alleles in relation to tamoxifen therapy [2012]

• American College of Obstetricians and Gynecologists
  • Aromatase Inhibitors in Gynecologic Practice [2018]
  • Tamoxifen and Uterine Cancer [2014]

• American Society of Clinical Oncology
  • Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update [2018]
  • Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression [2016]

• ASCO Educational Book
  • Advances in the Management of Menopausal Symptoms, Fertility Preservation, and Bone Health for Women With Breast Cancer on Endocrine Therapy [2023]

• Breast Cancer Research and Treatment
  • Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG) [2018]

• Clinical Cardiology
  • Are Aromatase Inhibitors Associated with Higher Myocardial Infarction Risk in Breast Cancer Patients? A Medicare Population-Based Study [2018]

• StatPearls
  • Tamoxifen

Western countries

• Breast
  • Improving medication adherence to endocrine therapy in breast cancer patients: a mixed-methods systematic review of effective communication strategies for healthcare providers [2025]

{Related topics}

• Topic
  • Breast cancer treatment